P3.03-047 Diagnostic Value of Secretary Leukocyte Peptide Inhibitor (SLPI) in Pleural Fluid in Malignant Pleural Mesothelioma

There is no established diagnostic marker for malignant pleural mesothelioma (MPM). The aim of this study was to evaluate the usefulness of secretary leukocyte peptide inhibitor (SLPI) in pleural fluid for the diagnosis of MPM. The study included 52 MPM patients, 69 patients of lung cancer with pleural effusion (LC), and 50 patients with benign asbestos pleural effusion (BAPE) that were included as a control group. Pleural fluid was collected...